Abbott announced before the market opened on Tuesday that its first quarter Diagnostics business revenues climbed 120 percent year over year.

Roche on Wednesday said its diagnostics sales during the first quarter 2021 grew 50 percent year over year, in part on demand for the company's COVID-19 products.

Autobio 's revenue was 2.978 billion yuan, while Liferiver reached was 2.052 billion yuan.

Recently, Beijing Strong Biotechnologies, Inc. successively reached strategic cooperation with Jilin Sinopharm and Liaoning Sinopharm; BEAVER completed the B round financing of tens of millions yuan; Demeter completed the A round of financing of tens of millions yuan.

In the first year of listing, Shenzhen New Industries Biomedical Engineering Co., Ltd. (Briefed as Snibe Co.,Ltd., Code No.: 300832. SZ) intends to repay shareholders well.

On April 15, 2021, the Wall Street Journal reported that Thermo Fisher, an American medical device giant would acquire PPD, a world-renowned CRO company for $17.4 billion.

On April 16, 2021, GEM Listing Committee announced that the IPO registration application of ACROBiosystems was approved.

On April 9, 2021, Chemclin Diagnostics Corporation (stock code 688468) successfully listed on SSESTARMarket of the Shanghai Stock Exchange.

On February 18, 2021, New Horizon Health was officially listed on HK stock exchange.

Recently， there are many IVD companies that complete the financing, including Ustar, GENFINE BIOTECH, Accunome,?Legendaibiochip and Vision?Medicals.

For many families, pets are like the existence of family members.Can the virus spread between humans and pets?

As of February 20, 2021, FDA has urgently authorized 14 COVID-19 antigen tests, involving 11 companies: Abbott、Ortho、Quidel 、BD、LumiraDx、Access Bio、Princeton BioMeditech、Luminostics、Celltrion、Quanterix、Ellume.

On the evening of February 19, FTSE Russell, an international index compilation company, announced the quarterly review results of its flagship index, adding 129 A-share targets in total. Edan Instruments (300206. SZ) officially entered the FTSE Russell.

Recently, a number of Chinese listed IVD companies released 2020 annual performance report, disclosing their revenue. Driven by the demand of testing products of COVID-19, the performance growth is very gratifying.

"Understanding which genes protect people from diabetes and cardiovascular disease will ultimately lead to better diagnosis and treatment of obese patients," the researchers said.